Compare LifeStance Health Group Inc. Common Stock (LFST) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LifeStance Health Group Inc. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? LifeStance Health Group Inc. Common Stock trades at $12.7 (market cap $4.76B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and LifeStance Health Group Inc. Common Stock is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold LifeStance Health Group Inc. Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LFST | SYRE | |
|---|---|---|
Market Cap | $4.76B | $7.35B |
Volume | 3,444,549 | 1,624,631 |
Sector | Health | Health |
52-Week High | $13.38 | $108.92 |
52-Week Low | $4.81 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.99B | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LifeStance Health Group (LFST) trades at $12.32, down 1.28% today, with strong technical momentum showing a bullish moving average signal. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $0.06 exceeding the $0.03 forecast. Revenue growth accelerated from $1.42B in 2025 to $1.6B in 2026, while net income improved significantly from $9.66M to $51M.
Wall Street maintains strong bullish sentiment with 82% buy ratings and a $14.14 consensus price target representing 15% upside. However, elevated valuation multiples (P/E 94.8) and overbought technical conditions near 52-week highs warrant caution. The mental healthcare provider benefits from industry tailwinds but faces execution risks amid competitive pressures.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About LifeStance Health Group Inc. Common Stock
LifeStance Health provides outpatient mental healthcare, including therapy, psychiatry, and medication management services.
Read more on LFST →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
